Skip to main content
PMC home page
Emerging Infectious Diseases logoLink to Emerging Infectious Diseases
. 1997 Jul-Sep;3(3):311–317. doi: 10.3201/eid0303.970307

Vancomycin-resistant enterococci outside the health-care setting: prevalence, sources, and public health implications.

L C McDonald 1, M J Kuehnert 1, F C Tenover 1, W R Jarvis 1
PMCID: PMC2627647  PMID: 9284375

Abstract

Although nosocomial acquisition and subsequent colonization of vancomycin-resistant enterococci (VRE), an emerging international threat to public health, has been emphasized in the United States, colonization among nonhospitalized persons has been infrequently documented. In contrast, in Europe, colonization appears to occur frequently in persons outside the health-care setting. An important factor associated with VRE in the community in Europe has been avoparcin, a glycopeptide antimicrobial drug used for years in many European nations at subtherapeutic doses as a growth promoter in food-producing animals. In Europe, evidence suggests that foodborne VRE may cause human colonization. Although avoparcin has never been approved for use in the United States, undetected community VRE transmission may be occurring at low levels. Further studies of community transmission of VRE in the United States are urgently needed. If transmission with VRE from unrecognized community sources can be identified and controlled, increased incidence of colonization and infection among hospitalized patients may be prevented.

Full Text

The Full Text of this article is available as a PDF (46.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aarestrup F. M., Ahrens P., Madsen M., Pallesen L. V., Poulsen R. L., Westh H. Glycopeptide susceptibility among Danish Enterococcus faecium and Enterococcus faecalis isolates of animal and human origin and PCR identification of genes within the VanA cluster. Antimicrob Agents Chemother. 1996 Aug;40(8):1938–1940. doi: 10.1128/aac.40.8.1938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aarestrup F. M. Occurrence of glycopeptide resistance among Enterococcus faecium isolates from conventional and ecological poultry farms. Microb Drug Resist. 1995 Fall;1(3):255–257. doi: 10.1089/mdr.1995.1.255. [DOI] [PubMed] [Google Scholar]
  3. Arthur M., Molinas C., Depardieu F., Courvalin P. Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J Bacteriol. 1993 Jan;175(1):117–127. doi: 10.1128/jb.175.1.117-127.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bates J., Jordens J. Z., Griffiths D. T. Farm animals as a putative reservoir for vancomycin-resistant enterococcal infection in man. J Antimicrob Chemother. 1994 Oct;34(4):507–514. doi: 10.1093/jac/34.4.507. [DOI] [PubMed] [Google Scholar]
  5. Bates J., Jordens Z., Selkon J. B. Evidence for an animal origin of vancomycin-resistant enterococci. Lancet. 1993 Aug 21;342(8869):490–491. doi: 10.1016/0140-6736(93)91613-q. [DOI] [PubMed] [Google Scholar]
  6. Boyle J. F., Soumakis S. A., Rendo A., Herrington J. A., Gianarkis D. G., Thurberg B. E., Painter B. G. Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci. J Clin Microbiol. 1993 May;31(5):1280–1285. doi: 10.1128/jcm.31.5.1280-1285.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Centers for Disease Control and Prevention (CDC) Nosocomial enterococci resistant to vancomycin--United States, 1989-1993. MMWR Morb Mortal Wkly Rep. 1993 Aug 6;42(30):597–599. [PubMed] [Google Scholar]
  8. Chow J. W., Kuritza A., Shlaes D. M., Green M., Sahm D. F., Zervos M. J. Clonal spread of vancomycin-resistant Enterococcus faecium between patients in three hospitals in two states. J Clin Microbiol. 1993 Jun;31(6):1609–1611. doi: 10.1128/jcm.31.6.1609-1611.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Coque T. M., Arduino R. C., Murray B. E. High-level resistance to aminoglycosides: comparison of community and nosocomial fecal isolates of enterococci. Clin Infect Dis. 1995 Apr;20(4):1048–1051. doi: 10.1093/clinids/20.4.1048. [DOI] [PubMed] [Google Scholar]
  10. Coque T. M., Tomayko J. F., Ricke S. C., Okhyusen P. C., Murray B. E. Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States. Antimicrob Agents Chemother. 1996 Nov;40(11):2605–2609. doi: 10.1128/aac.40.11.2605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Devriese L. A., Ieven M., Goossens H., Vandamme P., Pot B., Hommez J., Haesebrouck F. Presence of vancomycin-resistant enterococci in farm and pet animals. Antimicrob Agents Chemother. 1996 Oct;40(10):2285–2287. doi: 10.1128/aac.40.10.2285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Donnelly J. P., Voss A., Witte W., Murray B. E. Does the use in animals of antimicrobial agents, including glycopeptide antibiotics, influence the efficacy of antimicrobial therapy in humans? J Antimicrob Chemother. 1996 Feb;37(2):389–392. doi: 10.1093/jac/37.2.389. [DOI] [PubMed] [Google Scholar]
  13. Edmond M. B., Ober J. F., Weinbaum D. L., Pfaller M. A., Hwang T., Sanford M. D., Wenzel R. P. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis. 1995 May;20(5):1126–1133. doi: 10.1093/clinids/20.5.1126. [DOI] [PubMed] [Google Scholar]
  14. Ena J., Dick R. W., Jones R. N., Wenzel R. P. The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study. JAMA. 1993 Feb 3;269(5):598–602. [PubMed] [Google Scholar]
  15. Handwerger S., Raucher B., Altarac D., Monka J., Marchione S., Singh K. V., Murray B. E., Wolff J., Walters B. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis. 1993 Jun;16(6):750–755. doi: 10.1093/clind/16.6.750. [DOI] [PubMed] [Google Scholar]
  16. Handwerger S., Skoble J. Identification of chromosomal mobile element conferring high-level vancomycin resistance in Enterococcus faecium. Antimicrob Agents Chemother. 1995 Nov;39(11):2446–2453. doi: 10.1128/aac.39.11.2446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Howarth F., Poulter D. Vancomycin resistance: time to ban avoparcin. Lancet. 1996 Apr 13;347(9007):1047–1047. doi: 10.1016/s0140-6736(96)90187-7. [DOI] [PubMed] [Google Scholar]
  18. Jordens J. Z., Bates J., Griffiths D. T. Faecal carriage and nosocomial spread of vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother. 1994 Oct;34(4):515–528. doi: 10.1093/jac/34.4.515. [DOI] [PubMed] [Google Scholar]
  19. Klare I., Heier H., Claus H., Böhme G., Marin S., Seltmann G., Hakenbeck R., Antanassova V., Witte W. Enterococcus faecium strains with vanA-mediated high-level glycopeptide resistance isolated from animal foodstuffs and fecal samples of humans in the community. Microb Drug Resist. 1995 Fall;1(3):265–272. doi: 10.1089/mdr.1995.1.265. [DOI] [PubMed] [Google Scholar]
  20. Klare I., Heier H., Claus H., Reissbrodt R., Witte W. vanA-mediated high-level glycopeptide resistance in Enterococcus faecium from animal husbandry. FEMS Microbiol Lett. 1995 Jan 15;125(2-3):165–171. doi: 10.1111/j.1574-6968.1995.tb07353.x. [DOI] [PubMed] [Google Scholar]
  21. Klare I., Heier H., Claus H., Witte W. Environmental strains of Enterococcus faecium with inducible high-level resistance to glycopeptides. FEMS Microbiol Lett. 1993 Jan 1;106(1):23–29. doi: 10.1111/j.1574-6968.1993.tb05930.x. [DOI] [PubMed] [Google Scholar]
  22. Landman D., Quale J. M., Oydna E., Willey B., Ditore V., Zaman M., Patel K., Saurina G., Huang W. Comparison of five selective media for identifying fecal carriage of vancomycin-resistant enterococci. J Clin Microbiol. 1996 Mar;34(3):751–752. doi: 10.1128/jcm.34.3.751-752.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Linden P. K., Pasculle A. W., Manez R., Kramer D. J., Fung J. J., Pinna A. D., Kusne S. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis. 1996 Apr;22(4):663–670. doi: 10.1093/clinids/22.4.663. [DOI] [PubMed] [Google Scholar]
  24. Mato R., de Lencastre H., Roberts R. B., Tomasz A. Multiplicity of genetic backgrounds among vancomycin-resistant Enterococcus faecium isolates recovered from an outbreak in a New York City hospital. Microb Drug Resist. 1996 Fall;2(3):309–317. doi: 10.1089/mdr.1996.2.309. [DOI] [PubMed] [Google Scholar]
  25. Montecalvo M. A., Horowitz H., Gedris C., Carbonaro C., Tenover F. C., Issah A., Cook P., Wormser G. P. Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother. 1994 Jun;38(6):1363–1367. doi: 10.1128/aac.38.6.1363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Morris J. G., Jr, Shay D. K., Hebden J. N., McCarter R. J., Jr, Perdue B. E., Jarvis W., Johnson J. A., Dowling T. C., Polish L. B., Schwalbe R. S. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med. 1995 Aug 15;123(4):250–259. doi: 10.7326/0003-4819-123-4-199508150-00002. [DOI] [PubMed] [Google Scholar]
  27. Panagea S., Chadwick P. R. Heat tolerance of vancomycin resistant Enterococcus faecium. J Clin Pathol. 1996 Aug;49(8):687–689. doi: 10.1136/jcp.49.8.687. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sader H. S., Pfaller M. A., Tenover F. C., Hollis R. J., Jones R. N. Evaluation and characterization of multiresistant Enterococcus faecium from 12 U.S. medical centers. J Clin Microbiol. 1994 Nov;32(11):2840–2842. doi: 10.1128/jcm.32.11.2840-2842.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Shay D. K., Maloney S. A., Montecalvo M., Banerjee S., Wormser G. P., Arduino M. J., Bland L. A., Jarvis W. R. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis. 1995 Oct;172(4):993–1000. doi: 10.1093/infdis/172.4.993. [DOI] [PubMed] [Google Scholar]
  30. Shekar R., Chico G., Bass S. N., Strozewski K., Biddle J. Household transmission of vancomycin-resistant Enterococcus faecium. Clin Infect Dis. 1995 Dec;21(6):1511–1512. doi: 10.1093/clinids/21.6.1511. [DOI] [PubMed] [Google Scholar]
  31. Suppola J. P., Volin L., Valtonen V. V., Vaara M. Overgrowth of Enterococcus faecium in the feces of patients with hematologic malignancies. Clin Infect Dis. 1996 Oct;23(4):694–697. doi: 10.1093/clinids/23.4.694. [DOI] [PubMed] [Google Scholar]
  32. Swartz M. N. Hospital-acquired infections: diseases with increasingly limited therapies. Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2420–2427. doi: 10.1073/pnas.91.7.2420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Thal L. A., Chow J. W., Mahayni R., Bonilla H., Perri M. B., Donabedian S. A., Silverman J., Taber S., Zervos M. J. Characterization of antimicrobial resistance in enterococci of animal origin. Antimicrob Agents Chemother. 1995 Sep;39(9):2112–2115. doi: 10.1128/aac.39.9.2112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Uttley A. H., Collins C. H., Naidoo J., George R. C. Vancomycin-resistant enterococci. Lancet. 1988 Jan 2;1(8575-6):57–58. doi: 10.1016/s0140-6736(88)91037-9. [DOI] [PubMed] [Google Scholar]
  35. Van der Auwera P., Pensart N., Korten V., Murray B. E., Leclercq R. Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis. 1996 May;173(5):1129–1136. doi: 10.1093/infdis/173.5.1129. [DOI] [PubMed] [Google Scholar]
  36. Whitman M. S., Pitsakis P. G., DeJesus E., Osborne A. J., Levison M. E., Johnson C. C. Gastrointestinal tract colonization with vancomycin-resistant Enterococcus faecium in an animal model. Antimicrob Agents Chemother. 1996 Jun;40(6):1526–1530. doi: 10.1128/aac.40.6.1526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. van Belkun A., van den Braak N., Thomassen R., Verbrugh H., Endtz H. Vancomycin-resistant enterococci in cats and dogs. Lancet. 1996 Oct 12;348(9033):1038–1039. doi: 10.1016/s0140-6736(05)64973-2. [DOI] [PubMed] [Google Scholar]

Articles from Emerging Infectious Diseases are provided here courtesy of Centers for Disease Control and Prevention

RESOURCES